Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Studying nutrition symbols

This article was originally published in The Tan Sheet

Executive Summary

FDA proposes an "experimental study" on the effectiveness of front-of-package nutrition symbols on food products. According to a June 1 Federal Register 1notice, a contractor will survey 2,400 adults' responses to multiple food labels that vary in location and type of symbol. FDA proposed the study to show the level of consumer understanding of select nutrition symbols. Food companies support establishing a standard but voluntary labeling system that uses symbols to indicate the nutrition content of their products, according to remarks at a 2007 public hearing (2"The Tan Sheet" Sept. 17, 2007, p. 7). FDA's Center for Food Safety and Applied Nutrition also solicited comment on the use of nutrition symbols. The deadline for comments on the study proposal is July 31

You may also be interested in...



Food Industry Hungry For Voluntary Use Of Nutrition Symbols Standard

Food manufacturers and other industry stakeholders support establishing a standard but voluntary labeling system that uses symbols to indicate the nutrition content of their products, industry representatives said during a public hearing sponsored by FDA's Center for Food Safety and Applied Nutrition Sept. 10-11

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.

Topics

UsernamePublicRestriction

Register

PS103025

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel